EICHORCondition: Pancreatic Ductal Adenocarcinoma · Sponsor: Boehringer Ingelheim
This study has stopped recruitment. Adults with advanced pancreatic cancer participate in this study. The study tests a type of immunotherapy. It is a protein treatment (ATP150/ATP152/ATP162) combined with a virus (VSV-GP154) that may kill cancer cells and help the immune system fight cancer. The immunotherapy is combined with a study medicine called ezabenlimab. Ezabenlimab is an antibody that may also help the immune system fight cancer. The purpose is to find the highest dose of the immunotherapy that people with pancreatic cancer can tolerate when taken alone or together with ezabenlimab (Part A and B). To find out, researchers look at the number of participants with certain severe health problems. The original purpose of the subsequent Part C was to check whether the immunotherapy combined with ezabenlimab may increase survival and prevent the cancer getting worse over time. The recruitment into Part C was not continued and stopped. Participants can stay in the study as long as they tolerate the treatment or up to 1 year. During that time, they regularly visit the site. At all visits, the doctors closely check the health of the participants and note any severe health problems.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University of Southern California | Los Angeles, California, United States | — |
| University of California Los Angeles | Santa Monica, California, United States | — |
| University of Colorado Cancer Center | Aurora, Colorado, United States | — |
| University of Florida | Gainesville, Florida, United States | — |
| Orlando Health Cancer Institute | Orlando, Florida, United States | — |
| Karmanos Cancer Institute | Detroit, Michigan, United States | — |
| Perlmutter Cancer Center at NYU Langone Hospital - Long Island | New York, New York, United States | — |
| University Hospitals Cleveland Medical Center | Cleveland, Ohio, United States | — |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | — |
| START South Texas Accelerated Research Therapeutics, LLC | San Antonio, Texas, United States | — |
| Virginia Cancer Specialists, PC | Fairfax, Virginia, United States | — |
| Virginia Mason Medical Center | Seattle, Washington, United States | — |
+ 8 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05846516